Pharma Index going Upwards — Top 3 Drug Manufacturers You Should Consider
The market underestimates the growth potential of this stock
Merck & Company
Merck was recently selected as a Top Pick by stock experts Harp Sn and Paul Macdonald…
He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)
(A Top Pick September 14/17 – Down 4%) Nothing has changed. Still good dividends and fundamentals. Solid holding.
Like the stability. They are one of the leaders in immunotherapy and other lines of business. Core holding. Dividend yield is 3.1%. Market cap $165.8 billion. (Analysts’ price target is $69.16)